NeoGenomics (NEO)
(Delayed Data from NSDQ)
$13.53 USD
-0.01 (-0.07%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $13.52 -0.01 (-0.07%) 7:06 PM ET
2-Buy of 5 2
C Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$13.53 USD
-0.01 (-0.07%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $13.52 -0.01 (-0.07%) 7:06 PM ET
2-Buy of 5 2
C Value A Growth A Momentum A VGM
Zacks News
The Zacks Analyst Blog Highlights: Anthem, Ensign, NeoGenomics, Merit Medical Systems and Medpace
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Anthem, Ensign, NeoGenomics, Merit Medical Systems and Medpace
5 Healthcare Bets to Stay in Investors Good Books Next Year
by Zacks Equity Research
Based on a few key factors, we zero in on five stocks that show promise to retain the bull run in 2019.
QIAGEN Partners With Novartis to Expand CDx Tests Suite
by Zacks Equity Research
QIAGEN (QGEN) progresses well with the strategy to expand through strategic collaborations. The latest tie up will boost the company's companion diagnostic portfolio.
Is NeoGenomics (NEO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (NEO) Outperforming Other Medical Stocks This Year?
QIAGEN (QGEN) Partners NeoGenomics to Widen CDx Tests Reach
by Zacks Equity Research
The tie-up with NeoGenomics is expected to enable QIAGEN (QGEN) and pharmaceutical partners streamline the development and introduction of targeted drugs and companion diagnostics.
New Strong Buy Stocks for November 29th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Eyenovia Initiates Phase III Study for Mydriasis Candidate
by Zacks Equity Research
Eyenovia (EYEN) starts enrollment in the first phase III study of a two clinical study program to evaluate its mydriasis candidate, MicroStat. Stock rallies.
New Strong Buy Stocks for November 20th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
Top Ranked Momentum Stocks to Buy for November 9th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 9th
NeoGenomics (NEO) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 66.67% and 4.36%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
NeoGenomics (NEO) Q3 Earnings Preview: How Are Events Shaping Up?
by Zacks Equity Research
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EBS vs. NEO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EBS vs. NEO: Which Stock Is the Better Value Option?
EBS vs. NEO: Which Stock Is the Better Value Option?
by Zacks Equity Research
EBS vs. NEO: Which Stock Is the Better Value Option?
Zacks.com featured highlights: Live Nation Entertainment, NeoGenomics, Salesforce.com, Paycom Software and Covanta Holding
by Zacks Equity Research
Zacks.com featured highlights: Live Nation Entertainment, NeoGenomics, Salesforce.com, Paycom Software and Covanta Holding
Moving Average Crossover Alert: NeoGenomics (NEO)
by Zacks Equity Research
NeoGenomics, Inc. (NEO) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Explosive Returns with the Filtered Zacks Rank 5 Strategy
by Kevin Matras
Kevin Matras goes over the Filtered Zacks Rank 5 strategy. Learn how it can help you pick the best of the Zacks #1 Rank stocks. Highlighted stocks include CVGI, NEO and NTES.